ozanimod (Zeposia)
Jump to navigation
Jump to search
Indications
- multiple sclerosis
- ulcerative colitis[1] (FDA-approved)
Dosage
- titration to maintenance dose of 0.92 mg orally once daily
Capsules: 0.23 mg, 0.46 mg, 0.92 mg
Adverse effects
- most common (> 4%)
Mechanism of action
- sphingosine 1-phosphate receptor modulator
More general terms
References
- ↑ 1.0 1.1 Walsh N Ozanimod a Winner in Ulcerative Colitis - S1P receptor modulator effective for both induction and maintenance. MedPage Today December 10, 2020 https://www.medpagetoday.com/meetingcoverage/aibd/90136
Sandborn W, et al Ozanimod efficacy, safety, and histology in patients with moderate-to-severe ulcerative colitis during induction in the phase 3 True North study. Advances in Inflammatory Bowel Diseases (AIBD) 2020; Poster 025.
Danese S, et al Ozanimod efficacy, safety, and histology in patients with moderate-to-severe ulcerative colitis during maintenance in the phase 3 True North study. Advances in Inflammatory Bowel Diseases (AIBD) 2020; Poster 030.
Hamza Z Ozanimod Wins FDA Approval in Ulcerative Colitis
S1P receptor modulator indicated for moderate to severe disease. MedPage Today May 28, 2021 https://www.medpagetoday.com/gastroenterology/inflammatoryboweldisease/92844 - ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION ZEPOSIA (ozanimod) capsules, for oral use https://packageinserts.bms.com/pi/pi_zeposia.pdf